Susquehanna International Group, LLP Catalyst Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

$688 Billion
Q2 2025

A detailed history of Susquehanna International Group, LLP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 270,171 shares of CPRX stock, worth $5.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

270,171

Previous 235,872 14.54%

Holding current value

$5.55 Million

Previous $5.72 Million 2.5%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$21.4 - $26.31 $733,998 - $902,406	34,299 Added 14.54%	270,171 $5.86 Million
Q1 2025 May 14, 2025	BUY	$19.53 - $25.74 $2.67 Million - $3.52 Million	136,659 Added 137.74%	235,872 $5.72 Million
Q4 2024 Feb 14, 2025	SELL	$19.73 - $23.93 $434,237 - $526,675	-22,009 Reduced 18.16%	99,213 $2.07 Million
Q3 2024 Nov 14, 2024	BUY	$15.19 - $21.35 $550,576 - $773,852	36,246 Added 42.65%	121,222 $2.41 Million
Q2 2024 Aug 15, 2024	SELL	$14.68 - $16.92 $647,755 - $746,595	-44,125 Reduced 34.18%	84,976 $1.32 Million
Q1 2024 May 07, 2024	SELL	$13.18 - $17.11 $704,365 - $914,392	-53,442 Reduced 29.28%	129,101 $2.06 Million
Q4 2023 Feb 14, 2024	BUY	$11.78 - $17.29 $548,606 - $805,212	46,571 Added 34.25%	182,543 $3.07 Million
Q3 2023 Nov 14, 2023	SELL	$11.69 - $15.02 $616,086 - $791,584	-52,702 Reduced 27.93%	135,972 $1.59 Million
Q2 2023 Aug 11, 2023	SELL	$11.5 - $18.08 $73,910 - $116,200	-6,427 Reduced 3.29%	188,674 $2.54 Million
Q1 2023 May 16, 2023	SELL	$14.34 - $21.05 $1.35 Million - $1.98 Million	-94,174 Reduced 32.56%	195,101 $3.23 Million
Q4 2022 Feb 14, 2023	BUY	$12.25 - $19.5 $914,401 - $1.46 Million	74,645 Added 34.78%	289,275 $5.38 Million
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $1.09 Million - $2.41 Million	155,039 Added 260.17%	214,630 $2.75 Million
Q2 2022 Aug 15, 2022	SELL	$6.23 - $8.57 $323,455 - $444,945	-51,919 Reduced 46.56%	59,591 $418,000
Q1 2022 May 16, 2022	SELL	$5.31 - $8.31 $297,046 - $464,869	-55,941 Reduced 33.41%	111,510 $924,000
Q4 2021 Feb 14, 2022	SELL	$5.21 - $7.45 $140,456 - $200,844	-26,959 Reduced 13.87%	167,451 $1.13 Million
Q3 2021 Nov 15, 2021	SELL	$4.85 - $6.04 $543,665 - $677,059	-112,096 Reduced 36.57%	194,410 $1.03 Million
Q2 2021 Aug 11, 2021	BUY	$4.29 - $6.05 $591,273 - $833,847	137,826 Added 81.71%	306,506 $1.76 Million
Q1 2021 May 17, 2021	BUY	$3.45 - $4.69 $231,267 - $314,389	67,034 Added 65.95%	168,680 $778,000
Q4 2020 Feb 16, 2021	BUY	$2.97 - $3.83 $19,438 - $25,067	6,545 Added 6.88%	101,646 $339,000
Q3 2020 Nov 16, 2020	BUY	$2.97 - $5.08 $156,429 - $267,563	52,670 Added 124.13%	95,101 $282,000
Q2 2020 Aug 14, 2020	SELL	$3.48 - $5.05 $443,626 - $643,768	-127,479 Reduced 75.03%	42,431 $196,000
Q1 2020 May 15, 2020	SELL	$2.61 - $5.21 $66,171 - $132,089	-25,353 Reduced 12.98%	169,910 $654,000
Q4 2019 Feb 14, 2020	SELL	$3.67 - $5.7 $470,754 - $731,144	-128,271 Reduced 39.65%	195,263 $732,000
Q3 2019 Nov 14, 2019	BUY	$3.89 - $7.43 $675,529 - $1.29 Million	173,658 Added 115.87%	323,534 $1.72 Million
Q2 2019 Aug 16, 2019	BUY	$2.7 - $6.11 $14,455 - $32,712	5,354 Added 3.7%	149,876 $576,000
Q2 2019 Aug 14, 2019	BUY	$2.7 - $6.11 $261,748 - $592,327	96,944 Added 203.76%	144,522 $555,000
Q4 2018 Feb 14, 2019	BUY	$1.92 - $3.62 $66,975 - $126,276	34,883 Added 274.78%	47,578 $91,000
Q2 2018 Aug 14, 2018	SELL	$2.26 - $3.84 $52,655 - $89,468	-23,299 Reduced 64.73%	12,695 $40,000
Q4 2017 Feb 14, 2018	BUY	$2.51 - $4.4 $90,344 - $158,373	35,994	35,994 $141,000

Others Institutions Holding CPRX

# of Institutions

386

Shares Held

103M

Call Options Held

Put Options Held

277K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.11B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Catalyst Pharmaceuticals, Inc. Transaction History